PhaseI/II study of carboplatin plus nab-paclitaxel plus bevacizumab administered to advanced non-squamous non-small cell lung cancer.
- Conditions
- advanced non-squamous non-small cell lung cancer
- Registration Number
- JPRN-UMIN000013333
- Lead Sponsor
- agoya City West Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 35
Not provided
(1) Hemorrhagic Diathesis, coagulopathy (2) Presence of cardiovascular invasion (3) Presence of any tumor with cavitation (4) Presence of significant interstitial lung disease or lung fibrosis (5) Uncontrolled intercurrent illness (eg. hypertension, diabetes mellitus, gastro- intestinal fistula, symptomatic congestive heart failure, unstable angina pectoris, serious cardiac arrhythmia) (6) Ongoing/active infection (7) Arterial thrombotic events or significant vascular disease (8) Uncontrolled gastric ulcer (9) Gastrointestinal perforation within the past 12 months (10) Prior malignancy (11) Uncontrolled pleural effusion or ascites (12) Clinically significant pericardial effusion (13) Hypersensitivity history for test drugs (14) Pregnancy or breast-feeding
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method phase I: to determine recommended dose phaseII: response rate
- Secondary Outcome Measures
Name Time Method phaseII:to evaluate disease control rate, progression free survival, overall survival and safety profile